Press Enter to search · ESC to close

Macro

China NMPA Accepts Novo Nordisk’s CagriSema Weight-Loss Drug Application

Novo Nordisk said China’s National Medical Products Administration has accepted its marketing application for CagriSema (cagrilintide and semaglutide injection) for long-term weight management. The once-weekly subcutaneous fixed-dose combination pairs the long-acting amylin receptor agonist cagrilintide with the GLP-1 receptor agonist semaglutide, which act through different and complementary mechanisms on appetite and body-weight regulation pathways.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback